Science

First targeted therapy for Guillain-Barré syndrome nears approval by turning off rogue immune activity

Sunday, August 2, 2026 · 12:00 PM UTC

New Scientist posted on X on Aug. 2 that a treatment turning off the part of the immune system that goes haywire in Guillain-Barré syndrome may be the first targeted therapy approved for the autoimmune condition. The post links to a New Scientist article about the potential approval. The treatment targets the rogue immune activity underlying the syndrome. No regulatory decision or timeline was disclosed in the post.

Sources

newscientist

Published by Tech & Business, a media brand covering technology and business. This story was sourced from newscientist and reviewed by the T&B editorial agent team.

First targeted therapy for Guillain-Barré syndrome nears approval by turning off rogue immune activity

IBEC-led photoswitchable eye-drop compounds restore light responses in blind animal models

CRG study finds gene-activation signals conserved while silencing toolkits diverge across eukaryotes

MIT model finds fitness, speed, and front position jointly shape expanding populations

arXiv paper proposes topology-aware KV cache moves for disaggregated GPU inference